In postmenopausal women with advanced HR+, HER2-negative breast cancer when letrozole or anastrozole fails,

Prescribe AFINITOR plus exemestane to...

DOUBLE INHIBITION

DOUBLE INHIBITION

Up to 70% of cases of breast cancer have mutations in the PI3K/Akt/mTOR pathway; hyperactivation of this pathway can contribute to endocrine resistance.1-5

Double Median PFS

DOUBLE MEDIAN PFS

Median PFS was 7.8 months [95% CI, 6.9-8.5] with AFINITOR® (everolimus) Tablets plus exemestane vs 3.2 months [95% CI, 2.8-4.1] with placebo plus exemestane (HR=0.45 [95% CI, 0.38-0.54]; P<0.0001).6

Excerpts from the experts

Victoria: A Case Study of HR+, HER2-Negative Advanced Breast Cancer Following Progression on NSAI Therapy

Blackwell Video
Play Video Play Video

Kimberly Blackwell, MD

Professor of Medicine

Duke University

Richard Michaelson, MD

Chief Medical Officer for Oncology

Saint Barnabas Medical Center

Diane: A Case Study of HR+, HER2-Negative Advanced Breast Cancer Following Progression on NSAI Therapy

Mayer-Lipton Video
Play Video Play Video

Ingrid Mayer, MD

Breast Cancer Specialist

Vanderbilt University Medical Center

Allan Lipton, MD

Professor of Oncology

Milton S. Hershey Medical Center

Ellen: A Case Study of Progression to the Viscera Following NSAI Therapy in HR+, HER2-Negative Advanced Breast Cancer

Peacock Video
Play Video Play Video

Nancy Peacock, MD

Medical Oncologist

Tennessee Oncology

Denise A. Yardley, MD

Medical Oncologist, Senior

Investigator

Sarah Cannon Research Institute

Coverage and support* from the very beginning

Our program provides comprehensive support to you and your patients throughout the treatment journey with AFINITOR. Get appropriate patients started on treatment promptly with a 14-day free trial of AFINITOR, the $25 AFINITOR Co-Pay Card or foundational assistance, and coverage support from our reimbursement experts.

*Eligibility requirements exist for all components for the AFINITOR Patient Support Program.

Is it time for a different treatment approach?

In the BOLERO-2 trial, following progression on an NSAI,

50%

of patients in the endocrine monotherapy arm were estimated to have progressed at 3.2 months.6

Abbreviations: BOLERO-2, Breast Cancer Trials of Oral Everolimus-2; ER, estrogen receptor; HER2, human epidermal growth factor receptor 2; HR+, hormone receptor-positive; MOA, mechanism of action; mTOR, mammalian target of rapamycin; NSAI, nonsteroidal aromatase inhibitor; PFS, progression-free survival.